C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial

C4 Therapeutics Inc CCCC has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL). 

  • The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting.
  • Cohort A explored CFT7455 as a single agent and enrolled five patients with MM. All patients in Cohort A were highly refractory and heavily pretreated.
  • Four patients received single-agent CFT7455 at the starting dose of 50 μg per day. Two of these patients were dose reduced to 25 μg per day due to neutropenia, known on-target toxicity associated with IKZF1/3 degraders, the Company, noted.
  • Related: C4 Therapeutics Multiple Myeloma Candidate Scores FDA Orphan Drug Tag.
  • There were no serious adverse events reported, and no adverse events resulted in death or treatment discontinuation.
  • Three patients had the best-observed reductions in serum-free light chain (dFLC) differences ranging from 41% to 78%. One patient had an increase of 56% in dFLC.
  • The patient who achieved a 78% reduction in dFLC did not achieve a partial response due to measurable plasmacytomas, which were assessed as stable.
  • Three patients had the best response of the stable disease. Two patients had the best response of the progressive disease.
  • Price Action: CCCC shares are down 52.5% at $10.89 during the market session on the last check Friday.

Posted In: Briefswhy it's movingBiotechNewsHealth CareSmall CapMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.